Compare Freeport-McMoRan Inc (FCX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs ResMed Inc. — how do they compare? Freeport-McMoRan Inc trades at $73.32 (market cap $102.16B), while ResMed Inc. trades at $228.11 (market cap $31.89B). The key difference: Freeport-McMoRan Inc is far larger — about 3.2× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 69 Days and ResMed Inc. for 51 Days on average.
| FCX | RMD | |
|---|---|---|
Market Cap | $102.16B | $31.89B |
Volume | 9,047,971 | 618,314 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $277.88 |
52-Week Low | $38.65 | $182.82 |
Typical Hold Time | 69 Days | 51 Days |
Enterprise Value | $108.44B | $31.24B |
Dividend Yield | 0.84% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $71.87, down 0.97% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $73.27. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue for 2025 was $25.92 billion, with net income of $2.20 billion and a net margin of 11.38%. Recent news highlights strong copper demand driven by AI and data center growth, positioning FCX to benefit from favorable market trends.
The outlook for FCX is positive, supported by robust copper demand and expansion projects, but risks include rising production costs and potential regulatory investigations. Analyst sentiment is predominantly bullish, with 61% recommending buy. The stock offers growth potential from commodity tailwinds, though investors should monitor cost pressures and execution of growth initiatives.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
